R
Rosalba Siracusa
Researcher at University of Messina
Publications - 153
Citations - 3786
Rosalba Siracusa is an academic researcher from University of Messina. The author has contributed to research in topics: Oxidative stress & Medicine. The author has an hindex of 29, co-authored 109 publications receiving 1841 citations.
Papers
More filters
Journal ArticleDOI
Astrocytes: Role and Functions in Brain Pathologies
TL;DR: The current knowledge pertaining to astrocytes’ role in brain pathologies is described and the possibilities to target them as approach toward pharmacological therapies for neuro-pathologies are discussed.
Journal ArticleDOI
Focus on the Role of NLRP3 Inflammasome in Diseases.
Roberta Fusco,Rosalba Siracusa,Tiziana Genovese,Salvatore Cuzzocrea,Salvatore Cuzzocrea,Rosanna Di Paola +5 more
TL;DR: A focus on the available knowledge about the NLRP3 inflammasome role in disorders with a high impact on public health and the balance between the activation of the harmful and beneficial inflammaome so that new therapies can be created for patients with these diseases is provided.
Journal ArticleDOI
Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update.
Rosalba Siracusa,Rosanna Di Paola,Salvatore Cuzzocrea,Salvatore Cuzzocrea,Daniela Impellizzeri +4 more
TL;DR: Fibromyalgia is a syndrome characterized by chronic and widespread musculoskeletal pain, often accompanied by other symptoms, such as fatigue, intestinal disorders and alterations in sleep and mood.
Journal ArticleDOI
Anti-inflammatory and Anti-oxidant Activity of Hidrox® in Rotenone-Induced Parkinson's Disease in Mice.
Rosalba Siracusa,Maria Scuto,Roberta Fusco,Angela Trovato,Maria Laura Ontario,Roberto Crea,Rosanna Di Paola,Salvatore Cuzzocrea,Salvatore Cuzzocrea,Vittorio Calabrese +9 more
TL;DR: Hidrox® (HD) is subject to fewer regulations than traditional drugs to improve patients’ brain health and could represent a promising nutraceutical choice to prevent Parkinson’s disease.
Journal ArticleDOI
Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain
Daniela Impellizzeri,Giuseppe Bruschetta,Marika Cordaro,Rosalia Crupi,Rosalba Siracusa,Emanuela Esposito,Salvatore Cuzzocrea,Salvatore Cuzzocrea +7 more
TL;DR: These findings illustrate the superior anti-inflammatory action exerted by orally administered, micronized PEA-m and ultramicronizedPEA-um, versus that of nonmicronized PeaPure, in the rat paw carrageenan model of inflammatory pain.